Nivolumab and Urelumab Active in Melanoma Regardless of PD-L1 Status

Share this content:
In conjunction with urelumab, nivolumab may be an effective treatment for patients with advanced or metastatic melanoma.
In conjunction with urelumab, nivolumab may be an effective treatment for patients with advanced or metastatic melanoma.

In conjunction with urelumab, nivolumab may be an effective treatment for patients with advanced or metastatic melanoma, according to a press release from Bristol-Myers Squibb.1

Results from a phase 1/2 study (ClinicalTrials.gov Identifier: NCT02534506) of urelumab and nivolumab for patients with a hematologic or solid cancer indicate that 18 of 46 patients with melanoma enrolled to this study had a confirmed objective response.

The response rates were similar regardless of PD-L1 status: 50% of PD-L1 positive and 47% of PD-L1 negative patients achieved a confirmed objective response.

There was no significant increase of treatment-related toxicity among patients who received urelumab plus nivolumab compared to that with nivolumab alone.

RELATED: Binimetinib + Encorafenib Improves PFS vs Vemurafenib in Melanoma

Sixty-three percent of patients in the melanoma cohort had a treatment-related adverse event, including fatigue, increased alanine transaminase (ALT), anemia, and increased aspartate transaminase (AST).

Reference

  1. Phase 1/2 data combining urelumab with Opdivo (nivolumab) in hematologic and solid tumors suggest increased antitumor effect in patients with melanoma. Bristol-Myers Squibb website. http://news.bms.com/press-release/bmy/phase-12-data-combining-urelumab-opdivo-nivolumab-hematologic-and-solid-tumors-sug. Updated November 12, 2016. Accessed November 17, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs